血脂水平与胃癌的相关性

doi:10.3760/cma.j.cn371439-20221103-00036

国际肿瘤学杂志 ›› 2023, Vol. 50 ›› Issue (3): 183-185.doi: 10.3760/cma.j.cn371439-20221103-00036

血脂水平与胃癌的相关性

姬薇¹, 关泉林²(), 陈雅蕊¹, 焦福智¹, 罗倩文¹

¹兰州大学第一临床医学院，兰州 730000
²兰州大学第一医院肿瘤外科，兰州 730000

收稿日期:2022-11-03 修回日期:2022-11-17 出版日期:2023-03-08 发布日期:2023-04-12
通讯作者: 关泉林，Email： guanql@lzu.edu.cn
基金资助:
甘肃省重点研究计划(2017YFC0908302)

Correlation between blood lipid level and gastric cancer

Ji Wei¹, Guan Quanlin²(), Chen Yarui¹, Jiao Fuzhi¹, Luo Qianwen¹

¹First Clinical Medical College of Lanzhou University， Lanzhou 730000， China
²Department of Oncology Surgery， First Hospital of Lanzhou University， Lanzhou 730000， China

Received:2022-11-03 Revised:2022-11-17 Online:2023-03-08 Published:2023-04-12
Contact: Guan Quanlin， Email： guanql@lzu.edu.cn
Supported by:
Key Research Program of Gansu Province of China(2017YFC0908302)

摘要/Abstract

摘要：

胃癌患者常存在不同程度的血脂异常，且血脂变化与胃癌发生、发展及预后密切相关。胃癌中血脂代谢的机制也备受关注，可能与高密度脂蛋白胆固醇逆向转运胆固醇功能、抗氧化抗炎特性等机制有关。此外，他汀类药物或可降低患胃癌的风险及相关死亡率。进一步研究血脂水平与胃癌的相关性，旨在为未来胃癌预防与精准诊疗提供新的思路。

关键词: 胃肿瘤, 血脂异常, 羟甲基戊二酰基CoA还原酶抑制剂

Abstract:

Patients with gastric cancer often have different degrees of dyslipidemia， and the level of lipid changes is closely related to the occurrence， development and prognosis of gastric cancer. The mechanism of lipid metabolism in gastric cancer has also attracted much attention， and it may be related to the reverse cholesterol transport function， antioxidant and anti-inflammatory properties of high-density lipoprotein cholesterol. In addition， statins may reduce the risk of gastric cancer and associated mortality. Further research on the correlation between blood lipid levels and gastric cancer is aimed to provide new ideas for the future prevention and precision diagnosis and treatment of gastric cancer.

Key words: Stomach neoplasms, Dyslipidemia, Hydroxymethylglutaryl-CoA reductase inhibitors

姬薇, 关泉林, 陈雅蕊, 焦福智, 罗倩文. 血脂水平与胃癌的相关性[J]. 国际肿瘤学杂志, 2023, 50(3): 183-185.

Ji Wei, Guan Quanlin, Chen Yarui, Jiao Fuzhi, Luo Qianwen. Correlation between blood lipid level and gastric cancer[J]. Journal of International Oncology, 2023, 50(3): 183-185.

参考文献 27

[1]	He Y, Wang Y, Luan F, et al. Chinese and global burdens of gastric cancer from 1990 to 2019[J]. Cancer Med, 2021, 10(10): 3461-3473. DOI: 10.1002/cam4.3892. doi: 10.1002/cam4.3892
[2]	陈行辉, 李昌芳. 血脂水平与癌症的相关性研究进展[J]. 医学综述, 2018, 24(18): 3608-3612. DOI: 10.3969/j.issn.1006-2084.2018.18.014. doi: 10.3969/j.issn.1006-2084.2018.18.014
[3]	Nam SY, Park BJ, Nam JH, et al. Effect of Helicobacter pylori eradication and high-density lipoprotein on the risk of de novo gastric cancer development[J]. Gastrointest Endosc, 2019, 90(3): 448-456. e1. DOI: 10.1016/j.gie.2019.04.232. doi: S0016-5107(19)31659-1 pmid: 31034810
[4]	Sun H, Huang X, Wang Z, et al. Triglyceride-to-high density lipoprotein cholesterol ratio predicts clinical outcomes in patients with gastric cancer[J]. J Cancer, 2019, 10(27): 6829-6836. DOI: 10.7150/jca.35939. doi: 10.7150/jca.35939 pmid: 31839817
[5]	Li F, Du H, Li S, et al. The association between metabolic syndrome and gastric cancer in Chinese[J]. Front Oncol, 2018, 8: 326. DOI: 10.3389/fonc.2018.00326. doi: 10.3389/fonc.2018.00326 pmid: 30191141
[6]	Pih GY, Gong EJ, Choi JY, et al. Associations of serum lipid level with gastric cancer risk, pathology, and prognosis[J]. Cancer Res Treat, 2021, 53(2): 445-456. DOI: 10.4143/crt.2020.599. doi: 10.4143/crt.2020.599 pmid: 33253515
[7]	阎巍, 刘俊田, 刘子豪, 等. 血脂代谢与胃癌发病风险相关性的病例对照研究[J]. 中国肿瘤临床, 2021, 48(4): 186-191. DOI: 10.3969/j.issn.1000-8179.2021.04.965. doi: 10.3969/j.issn.1000-8179.2021.04.965
[8]	Wu Y, Xin J, Loehrer EA, et al. High-density lipoprotein, low-density lipoprotein and triglyceride levels and upper gastrointestinal cancers risk: a trans-ancestry Mendelian randomization study[J]. Eur J Clin Nutr, 2022, 76(7): 995-1002. DOI: 10.1038/s41430-022-01078-6. doi: 10.1038/s41430-022-01078-6
[9]	姜媛媛, 张琰. 初发胃癌分化程度与患者空腹血脂水平的相关性[J]. 中国老年学杂志, 2017, 37(14): 3502-3503. DOI: 10.3969/j.issn.1005-9202.2017.14.055. doi: 10.3969/j.issn.1005-9202.2017.14.055
[10]	Shen JG, Jin LD, Dong MJ, et al. Low level of serum high-density lipoprotein cholesterol in gastric cancer correlates with cancer progression but not survival[J]. Transl Cancer Res, 2020, 9(10): 6206-6213. DOI: 10.21037/tcr-20-1220. doi: 10.21037/tcr-20-1220 pmid: 35117231
[11]	Shin HJ, Roh CK, Son SY, et al. Prognostic value of hypocholesterolemia in patients with gastric cancer[J]. Asian J Surg, 2021, 44(1): 72-79. DOI: 10.1016/j.asjsur.2020.08.014. doi: 10.1016/j.asjsur.2020.08.014
[12]	Hu D, Peng F, Lin X, et al. Prediction of three lipid derivatives for postoperative gastric cancer mortality: the Fujian prospective investigation of cancer (FIESTA) study[J]. BMC Cancer, 2018, 18(1): 785. DOI: 10.1186/s12885-018-4596-y. doi: 10.1186/s12885-018-4596-y pmid: 30081869
[13]	Ma MZ, Yuan SQ, Chen YM, et al. Preoperative apolipoprotein B/apolipoprotein A1 ratio: a novel prognostic factor for gastric cancer[J]. Onco Targets Ther, 2018, 11: 2169-2176. DOI: 10.2147/OTT.S156690. doi: 10.2147/OTT.S156690
[14]	Yi J, Ren L, Wu J, et al. Apolipoprotein C1 (APOC1) as a novel diagnostic and prognostic biomarker for gastric cancer[J]. Ann Transl Med, 2019, 7(16): 380. DOI: 10.21037/atm.2019.07.59. doi: 10.21037/atm.2019.07.59 pmid: 31555694
[15]	Bian X, Liu R, Meng Y, et al. Lipid metabolism and cancer[J]. J Exp Med, 2021, 218(1): e20201606. DOI: 10.1084/jem.20201606. doi: 10.1084/jem.20201606
[16]	Maan M, Peters JM, Dutta M, et al. Lipid metabolism and lipophagy in cancer[J]. Biochem Biophys Res Commun, 2018, 504(3): 582-589. DOI: 10.1016/j.bbrc.2018.02.097. doi: 10.1016/j.bbrc.2018.02.097
[17]	Ganjali S, Ricciuti B, Pirro M, et al. High-density lipoprotein components and functionality in cancer: state-of-the-art[J]. Trends Endocrinol Metab, 2019, 30(1): 12-24. DOI: 10.1016/j.tem.2018.10.004. doi: 10.1016/j.tem.2018.10.004
[18]	Soran H, Schofield JD, Durrington PN. Antioxidant properties of HDL[J]. Front Pharmacol, 2015, 6: 222. DOI: 10.3389/fphar.2015.00222. doi: 10.3389/fphar.2015.00222 pmid: 26528181
[19]	Kazi DS, Penko JM, Bibbins-Domingo K. Statins for primary prevention of cardiovascular disease: review of evidence and recommendations for clinical practice[J]. Med Clin North Am, 2017, 101(4): 689-699. DOI: 10.1016/j.mcna.2017.03.001. doi: 10.1016/j.mcna.2017.03.001
[20]	Chushi L, Wei W, Kangkang X, et al. HMGCR is up-regulated in gastric cancer and promotes the growth and migration of the cancer cells[J]. Gene, 2016, 587(1): 42-47. DOI: 10.1016/j.gene.2016.04.029. doi: 10.1016/j.gene.2016.04.029 pmid: 27085483
[21]	Seo SI, Park CH, Kim TJ, et al. Aspirin, metformin, and statin use on the risk of gastric cancer: a nationwide population-based cohort study in Korea with systematic review and meta-analysis[J]. Cancer Med, 2022, 11(4): 1217-1231. DOI: 10.1002/cam4.4514. doi: 10.1002/cam4.4514
[22]	Yuan M, Han S, Jia Y, et al. Statins are associated with improved survival of patients with gastric cancer: a systematic review and meta-analysis[J]. Int J Clin Pract, 2022, 2022: 4938539. DOI: 10.1155/2022/4938539. doi: 10.1155/2022/4938539
[23]	Kwon TJ, Kim TJ, Lee H, et al. Statin use decreases the risk of metachronous gastric cancer in patients without Helicobacter pylori infection[J]. Cancers (Basel), 2021, 13(5): 1020. DOI: 10.3390/cancers13051020. doi: 10.3390/cancers13051020
[24]	Cheung KS, Chan EW, Wong AYS, et al. Statins were associated with a reduced gastric cancer risk in patients with eradicated Helicobacter pylori infection: a territory-wide propensity score matched study[J]. Cancer Epidemiol Biomarkers Prev, 2020, 29(2): 493-499. DOI: 10.1158/1055-9965.EPI-19-1044. doi: 10.1158/1055-9965.EPI-19-1044
[25]	Kwon MJ, Kang HS, Kim JH, et al. Association between statin use and gastric cancer: a nested case-control study using a national health screening cohort in Korea[J]. Pharmaceuticals (Basel), 2021, 14(12): 1283. DOI: 10.3390/ph14121283. doi: 10.3390/ph14121283
[26]	Liu Q, Xia H, Zhou S, et al. Simvastatin inhibits the malignant behaviors of gastric cancer cells by simultaneously suppressing YAP and β-catenin signaling[J]. Onco Targets Ther, 2020, 13: 2057-2066. DOI: 10.2147/OTT.S237693. doi: 10.2147/OTT.S237693
[27]	Ortiz N, Delgado-Carazo JC, Díaz C. Importance of mevalonate pathway lipids on the growth and survival of primary and metastatic gastric carcinoma cells[J]. Clin Exp Gastroenterol, 2021, 14: 217-228. DOI: 10.2147/CEG.S310235. doi: 10.2147/CEG.S310235 pmid: 34103960

血脂水平与胃癌的相关性

Correlation between blood lipid level and gastric cancer

RichHTML

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献 27

相关文章 15

编辑推荐

Metrics

本文评价

[1]	袁健, 黄燕华. Hp-IgG抗体联合血清DKK1、sB7-H3对早期胃癌的诊断价值[J]. 国际肿瘤学杂志, 2024, 51(6): 338-343.
[2]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[3]	解淑萍, 孙亚红, 汪超. 早期肿瘤标志物联合NLR、PLR预测胃癌免疫治疗疗效[J]. 国际肿瘤学杂志, 2024, 51(3): 157-165.
[4]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[5]	邵慧芳, 王学红, 芦永福. CST1在胃癌进展中的作用机制及临床意义[J]. 国际肿瘤学杂志, 2023, 50(8): 489-492.
[6]	朱思雨, 王学红, 李文茜, 刘曙. 胃癌患者血清FABP1水平及其与幽门螺杆菌感染的关系[J]. 国际肿瘤学杂志, 2023, 50(6): 336-341.
[7]	杨娅, 王慧礼, 刘艳, 郭金凤, 王春霞, 吕敏, 山长平. GCSH基因在胃癌SNU-1细胞增殖和凋亡中的作用研究[J]. 国际肿瘤学杂志, 2023, 50(5): 257-262.
[8]	全祯豪, 徐飞鹏, 黄哲, 黄先进, 陈日红, 孙开裕, 胡旭, 林琳. 沉默lncRNA FTX通过miR-22-3p/NLRP3炎症体通路抑制胃癌细胞增殖[J]. 国际肿瘤学杂志, 2023, 50(4): 202-207.
[9]	范珊琳, 汪品秀, 孔飞, 周玉洁, 袁文臻. 胃癌新辅助化疗后肿瘤退缩分级预测因素的研究进展[J]. 国际肿瘤学杂志, 2023, 50(2): 112-116.
[10]	杨俊, 李荣, 曾建昌. 复方苦参注射液联合SOX方案治疗老年晚期胃癌的临床疗效[J]. 国际肿瘤学杂志, 2023, 50(2): 82-86.
[11]	邓莉莉, 段星宇, 李保中. HER2靶向药物及其联合治疗方案在胃及食管胃结合部腺癌治疗中的研究进展[J]. 国际肿瘤学杂志, 2023, 50(12): 751-757.
[12]	李佳宜, 王跃, 尚兰兰, 徐兴, 赵岩. 人工智能技术在胃癌诊断与治疗中的实践与展望[J]. 国际肿瘤学杂志, 2023, 50(11): 677-682.
[13]	于晓鹏, 冯青青, 赵文飞, 赵文文, 魏红梅. 靶向治疗联合免疫检查点抑制剂在HER2阳性进展期胃癌中的应用[J]. 国际肿瘤学杂志, 2023, 50(10): 631-635.
[14]	李立立, 安有志, 王艳军. 替雷利珠单抗治疗MSI-H局部晚期胃癌患者1例[J]. 国际肿瘤学杂志, 2022, 49(7): 444-446.
[15]	杨娅, 宁晓飞, 李炳亮, 姚慧, 山长平, 吕敏. 原花青素通过诱导活性氧产生介导抗SNU-1胃癌细胞株的作用机制研究[J]. 国际肿瘤学杂志, 2022, 49(5): 257-262.